In monitoring a client receiving reteplase after an acute myocardial infarction, which adverse effect should the nurse be watchful for?

When monitoring a client receiving reteplase after an acute myocardial infarction, the nurse should be particularly vigilant for epistaxis. Reteplase is a thrombolytic agent used to dissolve blood clots and improve blood flow in the case of a heart attack. One of the common adverse effects associated with the use of thrombolytics is bleeding, as these medications inherently interfere with the body's ability to form clots.

Epistaxis, or nosebleeds, can occur as a result of the increased bleeding tendency. It is essential for nurses to assess the client for any signs of bleeding, including changes in vital signs, any unusual bruising, or active bleeding from mucous membranes, such as the nose. Monitoring for epistaxis is particularly important because it can signify a more serious issue related to the thrombolytic therapy, indicating that the client may be at risk for more significant hemorrhage elsewhere in the body.

While other symptoms like diarrhea, vomiting, or epigastric pain can occur in various contexts, they are not as directly linked to the administration of reteplase as epistaxis, thus making it crucial for the nurse to monitor for this specific adverse effect.